DXCM vs UNH

DexCom, Inc. (DXCM) presents a compelling investment opportunity despite near-term price underperformance, with strong fundamentals and accelerating earnings growth driving a significant valuation disconnect. The stock trades at a forward P/E of 28.6x, below the sector average of 36.6x, while delivering robust 21.6% YoY revenue growth and 109.9% YoY earnings growth—both well above peer medians. Profitability metrics are elite, including a 30.64% ROE and 20.05% operating margin, reflecting pricing power and operational leverage in the continuous glucose monitoring (CGM) market. Although insider selling raises caution, the strong analyst consensus of 'strong_buy' and improving earnings trajectory since 2023 suggest confidence in sustained growth ahead.

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.